Abstract
Anticentromere antibodies (ACA) are useful in assessing and classifying patients with mild variant of systemic sclerosis called calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias (CREST) syndrome. From their prognostic significance, we are interested in the prevalence and disease correlation in Thai patients. A total of 3,233 serum samples of patients with any musculoskeletal symptoms were sent for antinuclear antibody determination at Ramathibodi Immunology Laboratory Service between the years 1998 and 2001. Forty sera (1.23%) were ACA positive. These sera were from 27 patients with autoimmune diseases and 13 with nonautoimmune diseases. Among autoimmune group, scleroderma was the most common diagnosis (33.3%) with limited sclerosis being the most frequent variant. The percentages of autoimmune disease were almost the same among the low-titer (1:40) and the high-titer (1:640) groups. The study suggests that the prevalence of ACA in Thai patients is low. The presence of ACA detected in patients with vague musculoskeletal symptoms does not suggest a diagnosis of CREST syndrome. Even high-titer ACA can be found in nonautoimmune diseases.
Similar content being viewed by others
References
Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis: anticentromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625
Fritzler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526
Tuffanelli DL, McKeon F, Kleinsmith DM, Burnham TK, Kirschner M (1983) Anticentromere and anticentriole antibodies in the scleroderma spectrum. Arch Dermatol 119:560–566
Vazquez-Abad D, Grodzicky T, Senecal JL (1999) Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis. Clin Immunol 90:182–189
Chan HL, Lee YS, Hong HS, Kuo TT (1994) Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19:298–302
Sato S, Fujimoto M, Ihn H, Takehara K (1994) Antibodies to centromere and centriole in scleroderma spectrum disorders. Dermatology 189:23–26
Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI et al (1989) Prevalence of scleroderma spectrum disorders in the general populations of South Carolina. Arthritis Rheum 32:998–1002
Medsger TA (1994) Systemic sclerosis (scleroderma). In: Stein JH, Hutton JJ. Kohler Po et al (eds). Internal medicine, 4th edn. Mosby Year Book, St. Louise, MO, pp 2443–2449
Kallenberg CGM, Pastoor GW, Wouda AA et al (1982) Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 41:382–387
Chorzelski TP, Jablonska S, Beutner EH, Blaszczyk M, Jarzabek-Chorzelska M, Kencha D et al (1985) Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermatol 113:381–9
Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (1984) The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700–706
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderrma). Arthritis Rheum 23:581–590
Arnett FC, Edworthy SM, Block DA, Mcshane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Vlachoyiannopauplos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297–301
Caramaschi P, Biasi D, Manzo T, Carletto A, Poli F, Bambara LM (1995) Anticentromere antibody-clinical associations: a study of 44 patients. Rheumatol Int 14:253–255
McCarty GA, Rice JR, Bembe ML, Barada FA Jr (1983) Anticentromere antibody. Clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum 26:1–7
Miller HM, Littlejohn GO, Davidson A, Jones B, Topliss DJ (1987) The clinical significance of the anticentromere antibody. Br J Rheumatol 26:17–21
Sun D, Martinez A, Sullivan KF, Sharp GC, Hoch SO (1996) Detection of anticentromere antibodies using recombinant human CENP-A protein. Arthritis Rheum 39:863–867
Martinez A, Sun D, Billings PB, Swiderek KM, Sullivan KF, Hoch SO (1998) Isolation and comparison of natural and recombinant human CENP-A autoantigen. J Autoimmun 11:611–619
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pakunpanya, K., Verasertniyom, O., Vanichapuntu, M. et al. Incidence and clinical correlation of anticentromere antibody in Thai patients. Clin Rheumatol 25, 325–328 (2006). https://doi.org/10.1007/s10067-005-0005-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0005-4